Thomas J Gajewski

US Patent:

6716422, Apr 6, 2004

Filed:

Oct 8, 1998

Appl. No.:

09/168832

Inventors:

Thomas F. Gajewski - Chicago IL
Francesca Fallarino - Peruga, IT

Assignee:

ARCH Development Corporation - Chicago IL
Genetics Institute Incorporated - Cambridge MA

International Classification:

A61K 3820

US Classification:

424 852, 424 851, 424 937, 424 9371, 4241841, 4241851, 4242041, 4242651, 4242771, 4242781, 514 2, 530351, 530300

Abstract:

The invention provides methods of inducing the production of cytolytic T lymphocytes directed against malignancy or infectious agent by a mammal and treating such disease such that deleterious side effects are minimized and treatment of metastatic melanomas are surprisingly and dramatically improved.

US Patent:

7381401, Jun 3, 2008

Filed:

Jan 10, 2005

Appl. No.:

11/032516

Inventors:

Thomas F. Gajewski - Chicago IL, US

Assignee:

The University of Chicago - Chicago IL

International Classification:

A61K 49/00

US Classification:

424 92

Abstract:

T cell anergy has been correlated with defective Ras signaling. However, neither a causal relationship nor the mechanism of Ras hypoactivation have been established. Using adenoviral transduction of CAR Tg T cells to enable genetic manipulation in nonproliferating cells, we show that Ras61L restores IL-2 production and MAP kinase signaling in T cells anergized in vitro or in vivo. A gene array screen revealed upregulated diacylglycerol kinase (DGK) in the anergic state, which was confirmed by RT-PCR and Western blot analysis. A DGK inhibitor significantly restored IL-2 production by anergic cells. Our data support a causal role for DGK and defective Ras signaling in T cell anergy.

US Patent:

60803991, Jun 27, 2000

Filed:

Apr 23, 1998

Appl. No.:

9/064964

Inventors:

Thomas F. Gajewski - Chicago IL
Francesca Fallarino - Chicago IL

Assignee:

Arch Development Corporation - Chicago IL

International Classification:

A61K 3820
A61K 4505
A61K 3912
A61K 39002
C07K 1454

US Classification:

424 852

Abstract:

The invention provides methods of inducing the production of cytolytic T lymphocytes directed against malignancy or infectious agent by a mammal and treating such disease such that deleterious side effects are minimized and treatment of metastatic melanomas are surprisingly and dramatically improved.

US Patent:

20210139994, May 13, 2021

Filed:

Sep 18, 2020

Appl. No.:

16/948455

Inventors:

- Chicago IL, US
Yuanyuan ZHA - Chicago IL, US
Robbert M. SPAAPEN - Chicago IL, US
Thomas F. GAJEWSKI - Chicago IL, US

Assignee:

The University of Chicago - Chicago IL

International Classification:

C12Q 1/6886
G01N 33/569
G01N 33/574
G16H 50/30
A61K 31/713
A61K 45/06
C12N 15/113

Abstract:

Embodiments concern methods and composition related to anergic T-cells in patients, such as cancer patients.

US Patent:

20180312929, Nov 1, 2018

Filed:

Mar 27, 2018

Appl. No.:

15/937044

Inventors:

- Chicago IL, US
Yuanyuan ZHA - Chicago IL, US
Robbert M. SPAAPEN - Chicago IL, US
Thomas F. GAJEWSKI - Chicago IL, US

International Classification:

C12Q 1/6886
G16H 50/30
G06F 19/00
C12N 15/113
A61K 31/713
G01N 33/574
A61K 45/06
G01N 33/569

Abstract:

Embodiments concern methods and composition related to anergic T-cells in patients, such as cancer patients.

US Patent:

20160024593, Jan 28, 2016

Filed:

Mar 14, 2014

Appl. No.:

14/777123

Inventors:

- Chicago IL, US
Yuanyuan ZHA - Chicago IL, US
Robert M. SPAAPEN - Chicago IL, US
Thomas F. GAJEWSKI - Chicago IL, US

International Classification:

C12Q 1/68
G06F 19/00
A61K 45/06
C12N 15/113
A61K 31/713

Abstract:

Embodiments concern methods and composition related to anergic T-cells in patients, such as cancer patients. T cell anergy is a hyporesponsive state induced by TCR engagement in the absence of costimulation (Schwartz, 2003). Anergy induction was initially observed in vitro using chemically-fixed antigen presenting cells (APCs). Subsequently, it was found that anergy could be induced by immobilized anti-CD3 mAb or calcium ionophores (such as ionomycin) in vitro, and by superantigen and soluble antigenic peptide in vivo. Indirect evidence has suggested that T cell dysfunction in the tumor microenvironment and establishment of transplant tolerance is partially due to T cell anergy (Gajewski et al., 2011).